study ended prior enrollment of the first patient because of unexpected issues in the manufacturing process prevented production of adequate clinical batches

The purpose of this study is to assess the safety and the preliminary efficacy of a single infusion of stimulated autologous CD4+ T cells in patients with Relapsing-Remitting Multiple Sclerosis.

The study duration for the patients (from start of baseline to end of follow-up) is 270 days.

Inclusion Criteria:

• Males and females 18 to 60 years of age
• Patients closely followed up for at least one year prior to inclusion (i.e. prior to the start of the baseline phase) if the diagnosis of the disease was made more than one year ago, to ensure that all possible episodes of clinical relapses which occurred during this interval of time were recorded and documented
• Multiple sclerosis that meets the 2010 revised McDonald criteria
• Relapsing/remitting type of multiple sclerosis (which includes clinically isolated syndromes if imaging shows brain lesions disseminated in space and time)
• Radiologically active disease defined by at least one gadolinium-enhancing lesion on a T1-weighted magnetic resonance imaging brain scan performed recently (i.e. within 3 months prior to inclusion)
• Disease-modifying drug naïve patients or patients with stable and adequately taken disease-modifying therapy (interferon β-1, glatiramer acetate, or dimethyl fumarate) for at least six months before inclusion (NOTE: Other disease modifying drugs might be added at a later date, depending on the results of current investigations)
• EDSS Score <= 5.5
• Positive predictive test in vitro for patient's CD4+ cell reactivity to immunogenic peptide
• Women of childbearing age must have a negative pregnancy test and must use adequate contraception during the treatment and follow-up phase of the study (three pregnancy tests will be required prior to and during the study: (1) during the screening phase, (2) about one week prior to leukapheresis, and (3) about one week prior to re-infusion of autologous cells)
• Fully informed written consent obtained

Exclusion Criteria:

• Positive only for the HLA DRB1*0101, DRB1*0102, DRB1*0401, DRB1*0426 alleles or for the combination of the previous alleles.
• Evidence of clinical relapse and use of intravenous or oral corticosteroids within 30 days prior to inclusion
• Therapeutic escalation anticipated (including change of disease modifying drug), other than the cell-based immunotherapy of this study, within the next six months
• Significant coexisting systemic disease including renal insufficiency
• Positive serology for hepatitis B and C, AIDS and syphilis
• Participation in another interventional clinical study, currently or during the past three months